Precision Medicine Conference 2027

Why oncology

Why a precision medicine conference built around oncology works for vendors

A broad precision medicine conference puts your genomics, diagnostics or data platform in front of a wide audience: population genomics, rare disease, public health and several therapy areas at once. ImmunoMark narrows that to precision oncology, where companion diagnostics, biomarker-driven trial design and reimbursement are part of day-to-day programme decisions.

For a vendor, the difference shows up in the meeting list. The programme is oncology-only, and the audience is 55–60% biotech and pharma, with 45–50% in senior leadership. Your team spends less of each day qualifying who has a live programme and more of it discussing one.

ImmunoMark runs two parallel streams: Next-Gen Immuno-Oncology (NGIO) and Biomarkers & Companion Diagnostics. Precision medicine sits across both. In San Diego the second stream is titled Biomarkers, Companion Diagnostics & Precision Medicine, and the IO stream opens with the keynote Shaping the Future of Precision Immuno-Oncology Through Artificial Intelligence and Next-Generation Therapeutics.

Buyer roles

Who you meet at this translational medicine conference

The roles below come from the attendee profiles in the prospectus. Each one evaluates something different, and each has sessions on the real agendas that show what is on their mind.

Buyer role	What they are evaluating	Related sessions
Heads and Directors of Translational Medicine	Assays and data that link mechanism to patient response	San Diego: Decoding Response and Resistance to Immunotherapy in NSCLC Through Integrative Multi-Omic and AI Approaches. London: Translational Research: Bridging Academia & Industry
Biomarker Operations Leads	Platform capacity, multiplexing and consistency across studies	London: Multiplex & Programmable Biomarker Platforms
Companion diagnostics and precision medicine leads	Co-development partners and the regulatory route	London: Companion Diagnostics Co-development Strategies. San Diego: Global Regulatory Strategies for Companion Diagnostics and Precision Medicine
Bioinformatics and data science teams	Data integration, real-world evidence and AI tools	London: Real-World Evidence Integration into Biomarker Strategy. San Diego: Real-World Evidence and Digital Biomarkers Supporting Clinical Decision Making
Clinical development leads	Patient selection and biomarker-driven trial design	San Diego: Artificial Intelligence for Optimising Clinical Trial Design and Patient Selection. London: Clinical Trial Design in Immunotherapy: Adaptive & Biomarker-Driven Models
Business development and market access	Evidence of clinical and economic value	San Diego: Demonstrating Clinical and Economic Value in Precision Oncology. London: Companion Diagnostics Commercialisation & Reimbursement Strategy

The 2027 series

One precision oncology conference, three markets

A diagnostics conference on its own often misses the drug-side teams who commission the work. ImmunoMark puts both sides in the same building at each edition.

San Diego

10–11 February 2027. Launch edition, 300+ senior attendees expected, in one of the leading biotechnology and life sciences hubs. Stream 2 includes Advancing Next-Generation Precision Diagnostics Through Genomics and Molecular Technologies.

London

3–4 March 2027. 2nd annual, 400+ target attendees, 60% UK & Ireland and 40% rest of Europe. Stream 2 closes Day 1 with The Future of Biomarker-Driven Oncology.

Boston

June 2027. Ask us for the latest on this edition when you request the prospectus.

London 2026 gives a reference point for the format: 300+ attendees from 100+ companies, 70% senior decision-makers and 200+ meetings conducted. Companies that took part included Roche, AstraZeneca, GSK, Merck and Johnson & Johnson.

If you are choosing a precision medicine conference 2027 shortlist, the practical question is where your first customers sit. A sequencing or CGP provider selling into US biotech may start in San Diego, where the Stream 2 agenda also covers liquid biopsy and minimal residual disease monitoring. A data or real-world evidence company with European pharma accounts may start in London, where regulatory sessions cover EMA, FDA and MHRA pathways together. Vendors with customers in both regions can run the same package at each edition, three weeks apart, and use Boston in June to follow up with US accounts.

Packages

Packages for a precision oncology summit sponsor

Genomics, diagnostics and data platforms usually sell to both streams: IO teams need patient selection, and biomarker teams need the assays and analytics. That makes cross-stream reach more valuable to you than to a single-stream vendor.

Best fit

Headline

The only package with a talk across both streams. Exclusive to one company per edition, so it suits the platform that wants to own the precision oncology conversation at that edition.

Welcome speech and a 30-minute Day 1 keynote slot across both streams
15 pre-scheduled 1:1 meetings
20 x 12 ft exhibition space
Email campaign to the full pre-qualified database
“Powered by” branding; 10 delegate + 10 client passes

If Headline is taken

Platinum

Choose the stream closest to your first buyer, usually Biomarkers & Companion Diagnostics, and use meetings to reach the other.

30-minute talk on Day 1
10 pre-scheduled 1:1 meetings
10 x 6 ft booth and 1-minute video promotion
Attendee list a week before

Demo-led sales

Exclusive 1:1 Meetings

Data and analytics sales usually need a demo-length conversation. Twenty minutes with the right translational or data science lead is often enough to book the next step.

3, 5, 7 or 10 pre-arranged 20-minute meetings
2–4 delegate passes
Drinks reception passes

Ask whether Headline is still open for San Diego, London or Boston.

Check availability

Meetings

How 1:1 meetings work for a genomics or data vendor

Map your buyers to the table aboveDecide which roles matter: translational, CDx, data science or clinical development.
Review the delegate listThe full list with profiles arrives 10 days before the event. Select by role and by company programme, not by title alone.
Use the wishlistFlag priority contacts so the team can target them beyond your scheduled meetings.
Hold 20-minute meetings on siteBring one use case per buyer type. Twenty minutes rewards a focused question over a full platform tour.
Follow up from the delegate listEvery tier includes the delegate list with contact details, so you can reach the people you did not meet.

For edition detail, see the precision medicine pages for San Diego and London. If your platform also serves immunotherapy teams directly, the immuno-oncology summit page covers Stream 1. Background reading: the advanced therapies biomarker outlook.

Package details by edition: San Diego sponsorship opportunities and London sponsorship opportunities.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

How is ImmunoMark different from a general precision medicine conference for a sponsor?

It covers precision oncology only. Both streams, Next-Gen Immuno-Oncology and Biomarkers & Companion Diagnostics, are oncology, and the audience is 55–60% biotech and pharma with 45–50% senior leadership. Your team meets people with live oncology programmes rather than a mixed precision medicine audience.

Our platform serves both IO and biomarker teams. Which stream should we choose?

Platinum, Gold and Silver talks sit in one stream of your choice; most data and diagnostics vendors pick Biomarkers & Companion Diagnostics and use 1:1 meetings to reach IO teams. The Headline package is the only one whose Day 1 keynote slot runs across both streams, and it is exclusive to one company per edition.

Which roles can we meet?

The prospectus attendee profiles include Heads and Directors of Translational Medicine, Biomarker Operations Leads, Principal Scientists, Business Development and Licensing leads, and departments such as Companion Diagnostics, Precision Medicine, Regulatory Affairs and Bioinformatics / Data Science. You choose your meetings from the full delegate list with profiles, sent 10 days before the event.

Are real-world evidence and AI on the agenda?

Yes. San Diego includes Real-World Evidence and Digital Biomarkers Supporting Clinical Decision Making and Artificial Intelligence for Optimising Clinical Trial Design and Patient Selection. London includes Real-World Evidence Integration into Biomarker Strategy.

When and where are the 2027 editions?

San Diego on 10–11 February 2027 (launch edition, 300+ senior attendees expected), London on 3–4 March 2027 (2nd annual, 400+ target attendees) and Boston in June 2027. Packages are the same at each edition.

A Precision Medicine Conference Built Around Oncology Buyers

Get the prospectus and package availability